Healthcare Industry News: venous stent
News Release - January 24, 2014
VENITI, Inc. Announces First Uses of Veniti Vici Venous Stent SystemLive Case Demonstration Scheduled for Leipzig Interventional Course (LINC)
ST. LOUIS, Jan. 23, 2014 -- (Healthcare Sales & Marketing Network) -- VENITI announced today that patients in the European Union (EU) were successfully treated for symptomatic venous outflow obstruction of the lower extremities with the Veniti Vici(TM) venous stent System. These procedures mark the first uses in patients of this novel venous stent from VENITI.
More procedures using the Veniti Vici venous stent System are scheduled at various locations in the EU, including a live case demonstration at the Leipzig Interventional Course (LINC) on 28 January 2014.
The Veniti Vici venous stent was designed from inception to be compatible with the unique anatomy and pathology of the venous system to specifically address the unmet need for a dedicated venous stent. Hundreds of thousands of people around the world suffer from lower-extremity venous disease, and until recently, the only treatment options available involved the use of re-purposed vascular stents originally designed for use in the arterial system, which physicians know is vastly different from the venous system in terms of hemodynamics, physiology, pathophysiology and other important characteristics.
Mr. Stephen Black, a Consultant Vascular Surgeon at the prestigious St. George's Vascular Institute, St. George's Hospital, London, implanted Veniti Vici Stents in five patients on 14 and 15 January. "The Veniti Vici venous stent appears to have the radial strength and vein coverage to provide optimal results in patients with symptomatic outflow obstruction of the lower extremities," said Mr. Black. "Having a stent that was designed from its inception for use in veins makes this an important addition to my treatment options."
Dr. Peter Neglen, a noted pioneer in venous stenting, who was also present at St Georges on 14 and 15 January commented: "The Veniti Vici Stent placement today in patients represented the culmination of years of working with venous stent designs to better suit the unique characteristics of the venous anatomy and venous disease."
Dr. Gerard O'Sullivan at the prominent Galway University Hospitals, Galway, Ireland who implanted the Veniti Vici stent on 16 January also commented that "The Veniti Vici venous stent is a step forward in venous stenting to help treat patients suffering from venous outflow obstruction."
"We are pleased that the unique advantages of a stent designed specifically for the venous system—including end-to-end crush resistance, higher radial resistive force, flexibility, and continuous vein coverage—are available to physicians treating venous outflow obstructions in the lower extremities," noted Scott Solano, VENITI President and Chief Executive Officer. "We believe the Veniti Vici Stent offers significant patient benefit due to its venous-specific design."
Mr. Solano and Daniel Krelle, VENITI European Marketing Director, will attend LINC 28-31 January and will be available to meet attendees and the media at the VENITI booth (Number 37).
About VENITI, Inc.
VENITI is a leading provider of innovative medical devices singularly focused on venous care. With three product lines: The Veniti Vici(TM) venous stent System, the Veniti Veni(TM) RF Plus Ablation System, and the Veniti Vidi(TM) Inferior Vena Cava (IVC) Filter System, VENITI is offering significant benefit to patients who suffer from lower extremity venous outflow obstruction or varicose veins, as well as those at risk of pulmonary embolism.
The Veniti Vici(TM) venous stent System is CE Marked under the European Medical Device Directive (MDD) 93/42/EEC, and VENITI is seeking approval from the U.S. Food and Drug Administration (FDA) to begin clinical studies of the device in the United States. The Veniti Veni(TM) RF Plus Endovascular Ablation System is also CE Marked under the European Medical Device Directive (MDD) 93/42/EEC. The Veniti Vidi(TM) IVC Filter System is in early stages of clinical studies in New Zealand, and VENITI is seeking approval from the US FDA to begin clinical studies of the device in the United States. VENITI Headquarters is located in St. Louis, Missouri, USA while its Research & Development and Manufacturing divisions are located in Fremont, California, USA. For more information, call +1 314 282 3753 or visit www.veniti.com.
The Veniti Vici venous stent System is CE Marked under the European Medical Device Directive (93/42/EEC); it is not available for sale in the United States. VENITI, the VENITI logo, and VENITI VICI are trademarks of VENITI, Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.